PTC Therapeutics (NASDAQ:PTCT) Shares Up 8.3% – Here’s What Happened

Posted by Brenda Bartman on Jun 17th, 2026

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) were up 8.3% on Wednesday . The company traded as high as $79.60 and last traded at $79.3320. Approximately 861,446 shares changed hands during trading, a decline of 34% from the average daily volume of 1,304,292 shares. The stock had previously closed at $73.27.

Analysts Set New Price Targets

A number of research analysts recently weighed in on PTCT shares. Barclays reaffirmed an “overweight” rating and set a $120.00 price objective on shares of PTC Therapeutics in a report on Monday, February 23rd. Truist Financial raised PTC Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Wall Street Zen lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Wells Fargo & Company upped their price objective on PTC Therapeutics from $86.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of PTC Therapeutics in a report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $91.36.

Read Our Latest Stock Report on PTC Therapeutics

PTC Therapeutics Price Performance

The stock has a 50-day simple moving average of $70.83 and a 200 day simple moving average of $71.98. The company has a market capitalization of $6.55 billion, a PE ratio of -33.87, a P/E/G ratio of 3.53 and a beta of 0.56.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.42. The company had revenue of $272.55 million for the quarter, compared to the consensus estimate of $217.42 million. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.PTC Therapeutics’s quarterly revenue was up 43.5% compared to the same quarter last year. During the same period in the previous year, the business earned $10.04 earnings per share. As a group, research analysts predict that PTC Therapeutics, Inc. will post 0.78 EPS for the current fiscal year.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, CEO Matthew B. Klein sold 12,572 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $72.95, for a total transaction of $917,127.40. Following the sale, the chief executive officer directly owned 393,998 shares in the company, valued at approximately $28,742,154.10. The trade was a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Mark Elliott Boulding sold 2,812 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $72.18, for a total value of $202,970.16. Following the sale, the vice president owned 105,212 shares in the company, valued at approximately $7,594,202.16. The trade was a 2.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,148 shares of company stock valued at $7,001,475 in the last 90 days. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of PTC Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. UMB Bank n.a. purchased a new stake in shares of PTC Therapeutics in the fourth quarter valued at $26,000. Smartleaf Asset Management LLC lifted its position in shares of PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 236 shares in the last quarter. Optiver Holding B.V. lifted its position in shares of PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 249 shares in the last quarter. Comerica Bank lifted its position in shares of PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 469 shares in the last quarter. Finally, Salomon & Ludwin LLC purchased a new stake in shares of PTC Therapeutics in the fourth quarter valued at $41,000.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.